SEC Form 8-K Summary
Business Context and Reporting Period
Tivic Health Systems, Inc. filed a Form 8-K on November 14, 2023, reporting that it issued a press release regarding financial results for the third quarter ended September 30, 2023. The provided filing identifies Tivic Health Systems, Inc. as the registrant, not Valion Bio, Inc.
The company is incorporated in Delaware, trades common stock under the symbol TIVC on Nasdaq, and qualifies as an emerging growth company.
Financial Metrics
The filing references third-quarter financial results contained in Exhibit 99.1, but the provided text does not include the press release or clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes Versus Prior Period
The filing text does not provide a clear comparison with the prior comparable period. Any changes in operating results, financial condition, or cash usage would need to be obtained from Exhibit 99.1 or the company’s related quarterly filing.
Guidance, Outlook, Risks, and Unusual Items
No specific financial guidance or outlook is provided in the filing text. The filing includes standard forward-looking-statement warnings that actual results may differ materially because of known and unknown risks, uncertainties, and other factors. It refers investors to the company’s SEC filings for additional risk disclosures.
The information was furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference in a subsequent filing.
Important Facts for Investors to Verify
- Confirm that the intended issuer is Tivic Health Systems, Inc. rather than Valion Bio, Inc.
- Review Exhibit 99.1 for the omitted third-quarter revenue, earnings, cash flow, liquidity, and balance-sheet data.
- Compare the September 30, 2023 results with the prior-year and prior-quarter periods.
- Review the company’s quarterly filing for debt, going-concern considerations, liquidity risks, and material contingencies.
- Assess any guidance or management commentary in the referenced press release, which is not included in the provided filing text.